[go: up one dir, main page]

AR071255A1 - Derivados de sulfonatos de dioxoantraceno, composiciones farmaceuticas, uso para preparar medicamentos y metodo de preparacion de dichos derivados - Google Patents

Derivados de sulfonatos de dioxoantraceno, composiciones farmaceuticas, uso para preparar medicamentos y metodo de preparacion de dichos derivados

Info

Publication number
AR071255A1
AR071255A1 ARP080104929A ARP080104929A AR071255A1 AR 071255 A1 AR071255 A1 AR 071255A1 AR P080104929 A ARP080104929 A AR P080104929A AR P080104929 A ARP080104929 A AR P080104929A AR 071255 A1 AR071255 A1 AR 071255A1
Authority
AR
Argentina
Prior art keywords
group
formula
derivatives
so3r6
independently
Prior art date
Application number
ARP080104929A
Other languages
English (en)
Inventor
Stefano Carlino
Napoli Alessandro Di
Original Assignee
Medidom Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39262809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR071255(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medidom Lab filed Critical Medidom Lab
Publication of AR071255A1 publication Critical patent/AR071255A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/57—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • C07C309/60—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)

Abstract

Compuestos que pueden tener actividad anti-inflamatoria tienen la formula general (1): en donde R1, R2, R3 son cada uno independientemente H o un grupo alquilo C1-4 o un grupo acilo C2-4; R4 y R5 son cada uno independientemente H o un grupo de la formula -SO3R6, en donde R6 es H o un grupo alquilo C1-4 o un grupo acilo C2-4; con la condicion de que al menos uno de R4 y R5 es un grupo de la formula -SO3R6, o una sal farmacéuticamente aceptable del mismo. Reivindicacion 9: Una composicion farmacéutica que comprende un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 3, o una sal farmacéuticamente aceptable del mismo como un ingrediente activo. Reivindicacion 13: Uso de un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 3 para la fabricacion de un medicamento para el tratamiento de condiciones que son mediadas o influenciadas por citoquinas pro-inflamatorias de la familia de la IL-1. Reivindicacion 14: Método para la preparacion de un compuesto de la formula (1) en donde R1, R2, R3 son cada uno independientemente H o un grupo alquilo C1-4 o un grupo acilo C2-4; R4 y R5 son cada uno independientemente H o un grupo de formula -SO3R6, en donde R6 es H o un grupo alquilo C1-4 o grupo acilo C2-4; con la condicion de que al menos uno de R4 y R5 es un grupo de la formula -SO3R6 o una sal farmacéuticamente aceptable del mismo, que comprende tratar el compuesto de la formula (2) en donde R1, R2, R3 son H, con ácido sulfurico concentrado.
ARP080104929A 2007-11-16 2008-11-12 Derivados de sulfonatos de dioxoantraceno, composiciones farmaceuticas, uso para preparar medicamentos y metodo de preparacion de dichos derivados AR071255A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07022268A EP2060562A1 (en) 2007-11-16 2007-11-16 Dioxoanthracene sulphonate derivatives

Publications (1)

Publication Number Publication Date
AR071255A1 true AR071255A1 (es) 2010-06-09

Family

ID=39262809

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104929A AR071255A1 (es) 2007-11-16 2008-11-12 Derivados de sulfonatos de dioxoantraceno, composiciones farmaceuticas, uso para preparar medicamentos y metodo de preparacion de dichos derivados

Country Status (19)

Country Link
US (2) US8754128B2 (es)
EP (2) EP2060562A1 (es)
JP (1) JP5512532B2 (es)
KR (1) KR101527620B1 (es)
CN (1) CN101861301B (es)
AR (1) AR071255A1 (es)
AU (1) AU2008322341B2 (es)
BR (1) BRPI0819320B1 (es)
CA (1) CA2704630C (es)
CL (1) CL2008003378A1 (es)
CO (1) CO6270356A2 (es)
DK (1) DK2220036T3 (es)
ES (1) ES2400028T3 (es)
MX (1) MX2010004800A (es)
MY (1) MY153945A (es)
PT (1) PT2220036E (es)
RU (1) RU2482109C2 (es)
UA (1) UA99745C2 (es)
WO (1) WO2009063427A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5933264B2 (ja) 2009-07-16 2016-06-08 サンスター株式会社 プロテオグリカン含有物
WO2012099216A1 (ja) 2011-01-19 2012-07-26 国立大学法人弘前大学 プロテオグリカンの大量調製法
CN104507484B (zh) * 2012-07-25 2019-08-30 国立大学法人弘前大学 变形性关节病预防或治疗用组合物
CN103110617A (zh) * 2013-03-22 2013-05-22 中国人民解放军肾脏病研究所 一种双醋瑞因在制备治疗糖尿病肾病药物中的用途
US20160252954A1 (en) * 2015-02-27 2016-09-01 Microsoft Technology Licensing, Llc Control apparatus
WO2017123672A1 (en) * 2016-01-12 2017-07-20 Lawrence Chan Combination treatment for inflammatory diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA761627B (en) 1976-03-16 1978-01-25 C Friedmann Improvements in or relating to the treatment of arthritis
GB9103075D0 (en) * 1991-02-13 1991-03-27 Washington Odur Ayuko Trinitrobenzene derivatives and their therapeutic use
DE4120990C2 (de) 1991-06-25 1995-07-27 Madaus Ag Verfahren zur Herstellung von Diacetylrhein
CZ26693A3 (en) * 1992-02-28 1993-12-15 Lilly Industries Ltd Pharmaceutical compositions
IT1264545B1 (it) 1993-07-30 1996-10-02 Medidom Lab Procedimento per la preparazione della diacereina
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
AR026801A1 (es) 2000-01-12 2003-02-26 Medidom Lab Sustancias para uso en el tratamiento de la psoriasis
WO2002007639A1 (en) 2000-07-24 2002-01-31 Cbite, Inc. Disposable articulator having at least one continuous opening for acceptance of stabilization means
US6610750B1 (en) 2000-09-15 2003-08-26 Laboratoires Negma Treatment of osteoarthritis
US20020128317A1 (en) 2001-01-23 2002-09-12 Laboratories Negma Treatment of pathological conditions characterized by an increased IL-1 level
US20040198716A1 (en) * 2001-02-05 2004-10-07 Dorit Arad Cysteine protease inhimbitors
US6797727B2 (en) * 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
RU2246485C1 (ru) * 2003-11-04 2005-02-20 Государственное образовательное учреждение высшего профессионального образования "Ивановский государственный химико-технологический университет" (ГОУВПО "ИГХТУ") 2,3-дикарбокси-6-сульфоантрахинон
RU2280027C1 (ru) * 2005-03-18 2006-07-20 Государственное образовательное учреждение высшего профессионального образования "Ивановский государственный химико-технологический университет" (ГОУВПО "ИГХТУ") 2,3-дикарбокси-5,8-диметокси-6-сульфоантрахинон

Also Published As

Publication number Publication date
AU2008322341B2 (en) 2013-02-21
RU2482109C2 (ru) 2013-05-20
JP5512532B2 (ja) 2014-06-04
RU2010124422A (ru) 2011-12-27
JP2011503170A (ja) 2011-01-27
MX2010004800A (es) 2010-05-20
HK1147738A1 (en) 2011-08-19
BRPI0819320A2 (pt) 2020-09-08
CN101861301B (zh) 2013-05-29
KR101527620B1 (ko) 2015-06-09
EP2220036B1 (en) 2012-12-26
BRPI0819320B1 (pt) 2021-11-09
AU2008322341A1 (en) 2009-05-22
CL2008003378A1 (es) 2011-04-01
EP2060562A1 (en) 2009-05-20
EP2220036A1 (en) 2010-08-25
CA2704630C (en) 2016-01-19
US20150011636A1 (en) 2015-01-08
US8754128B2 (en) 2014-06-17
US20110054032A1 (en) 2011-03-03
WO2009063427A1 (en) 2009-05-22
CA2704630A1 (en) 2009-05-22
MY153945A (en) 2015-04-15
CO6270356A2 (es) 2011-04-20
PT2220036E (pt) 2013-03-05
KR20100097162A (ko) 2010-09-02
ES2400028T3 (es) 2013-04-05
DK2220036T3 (da) 2013-03-25
CN101861301A (zh) 2010-10-13
UA99745C2 (en) 2012-09-25

Similar Documents

Publication Publication Date Title
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
UY39032A (es) Compuestos heterocíclicos como agentes antivirales
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
EA201201031A1 (ru) Ингибиторы вируса гепатита с
EA201171376A1 (ru) Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
MX384836B (es) Agentes antivirales contra la hepatitis b
EA202090514A1 (ru) Противовирусное средство против гепатита в
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112014010105A2 (pt) aminas de c-28 de derivados de ácido betulínico modificado por c-3 como inibidores de maturação de hiv
AR071255A1 (es) Derivados de sulfonatos de dioxoantraceno, composiciones farmaceuticas, uso para preparar medicamentos y metodo de preparacion de dichos derivados
AR081638A1 (es) Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del vih
DOP2012000011A (es) Formulacion farmaceutica
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
UY33473A (es) Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
PE20121523A1 (es) Metodo de tratamiento
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS

Legal Events

Date Code Title Description
FG Grant, registration